Skip to content
Ibumix
  • Technology
    • Bioavailability
    • The tablet problem
    • Lipid & liquid-crystal delivery
    • GRAS & established materials
    • TECHNOLOGY – The Ibumix™ Platform
    • Science and data
    • The Structural Problem Behind Poor Drug Solubility
    • Products
    • Drug-delivery and formulation glossary
  • Company
    • About Ibumix
    • Investor overview
    • Newsroom
    • Connect
  • Insights
Ibumix
  • Technology
    • Bioavailability
    • The tablet problem
    • Lipid & liquid-crystal delivery
    • GRAS & established materials
    • TECHNOLOGY – The Ibumix™ Platform
    • Science and data
    • The Structural Problem Behind Poor Drug Solubility
    • Products
    • Drug-delivery and formulation glossary
  • Company
    • About Ibumix
    • Investor overview
    • Newsroom
    • Connect
  • Insights

Tag: GLP-1

Two Roads to One Pill: Novo Nordisk's oral semaglutide tolerates the bioavailability ceiling with SNAC, while Eli Lilly's Foundayo (orforglipron) avoids it as a small molecule
12 August 202617 August 2026TechnologyBy George Forrest

Two Roads to One Pill

Ozempic is a pill now, but oral bioavailability wasn’t solved. How Novo Nordisk and Eli Lilly reached comparable results by two opposite routes.

Read more
21 July 202612 August 2026TechnologyBy George Forrest

The Second Battle, Opened From the Inside

The Second Battle, Opened From the Inside Octreotide, acromegaly and the tight-junction trick that takes on the gut wall directly Rybelsus proved […]

Read more
© 2026 Ibumix.